The impact of donor naive and memory T cell subsets on patient outcome following allogeneic stem cell transplantation: Relationship between infused donor CD4+/CCR7+ T cell subsets and acute graft-versus-host disease;Impact de la composition du greffon sur le devenir des patients après une allogreffe de cellules souches hématopoïétiques: Corrélation entre proportion des lymphocytes T CD4+ du greffon exprimant le CCR7et la survenue d'une GVH

Pathologie Biologie

Volumn 62, Issue 3, 2014, Pages 123-128

  Choufi, B ^a,b   Thiant, S ^a   Trauet, J ^a   Cliquennois, M ^a,b,c   Cherrel, M ^a   Boulanger, F ^c   Coiteux, V ^a   Magro, L ^a   Labalette, M ^a   Yakoub Agha, I ^a,b,c  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Centre hospitalier de Boulogne sur Mer   (France)

^c ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Acute GVHD; Allogeneic stem cell transplantation; T cells CCR7

Indexed keywords

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CCR7+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MEMORY T LYMPHOCYTE; OUTCOME ASSESSMENT; T LYMPHOCYTE SUBPOPULATION; ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLOGRAFT; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CHILD; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOLOGIC NEOPLASMS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; LIVING DONOR; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDY; TRANSPLANTATION; TREATMENT OUTCOME; YOUNG ADULT;

CCR7 PROTEIN, HUMAN; CHEMOKINE RECEPTOR CCR7;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLOGRAFTS; BONE MARROW TRANSPLANTATION; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CHILD; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; LIVING DONORS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; RECEPTORS, CCR7; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84902540223     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2014.02.013     Document Type: Article

References (45)

1. Hessner M.J., Endean D.J., Casper J.T., Horowitz M.M., Keever-Taylor C.A., Roth M., et al. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 1995, 86(10):3987-3996.
2. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990, 75(3):555-562.
3. Lee S.J., Klein J.P., Barrett A.J., Ringden O., Antin J.H., Cahn J.Y., et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002, 100(2):406-414.
4. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979, 300(19):1068-1073.
5. Robinet E., Lapierre V., Tayebi H., Kuentz M., Blaise D., Tiberghien P. Blood versus marrow hematopoietic allogeneic graft. Transfus Apher Sci 2003, 29(1):53-59.
6. Storek J., Dawson M.A., Storer B., Stevens-Ayers T., Maloney D.G., Marr, et al. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood 2001, 97(11):3380-3389.
7. Yakoub-Agha I., Saule P., Magro L., Cracco P., Duhamel A., Coiteux V., et al. Immune reconstitution following myeloablative allogeneic hematopoietic stem cell transplantation: the impact of expanding CD28negative CD8+ T cells on relapse. Biol Blood Marrow Transplant 2009, 15(4):496-504.
8. Sallusto F., Geginat J., Lanzavecchia A. Central memory and effector memory T cell subsets: function generation and maintenance. Annu Rev Immunol 2004, 22:745-763.
9. Amyes E., McMichael A.J., Callan M.F. Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets. J Immunol 2005, 175(9):5765-5773.
10. Sallusto F., Lenig D., Forster R., Lipp M., Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999, 401(6754):708-712.
11. Yakoub-Agha I., Saule P., Depil S., Micol J.B., Grutzmacher C., Boulanger-Villard, et al. A high proportion of donor CD4+ T cells expressing the lymph node-homing chemokine receptor CCR7increases incidence and severity of acute graft-versus-host disease in patients undergoing allogeneic stem cell transplantation for hematological malignancy. Leukemia 2006, 20(9):1557-1565.
12. Yakoub-Agha I., Saule P., Depil S., Grutzmacher C., Boulanger F., Magro L., et al. Comparative analysis of naive and memory CD4+ and CD8+ T-cell subsets in bone marrow and G-CSF-mobilized peripheral blood stem cell allografts: impact of donor characteristics. Exp Hematol 2007, 35(6):861-871.
13. Bay J.O., Peffault de Latour R., Bruno B., Coiteux V., Guillaume T., Hicheri Y., et al. [Diagnosis and treatment of CMV and EBV reactivation as well as post-transplant lymphoproliferative disorders following allogeneic stem cell transplantation: an SFGM-TC report]. Pathol Biol 2013, 61(4):152-154.
14. Deconinck E., Dalle J.H., Berceanu A., Chevallier P., Dulery R., Garnier A., et al. [How I manage respiratory syncytial virus human herpesvirus 6and adenovirus reactivation or infection after allogeneic stem cell transplantation: a report of the SFGM-TC]. Pathol Biol 2013, 61(4):149-151.
15. Appay V., Reynard S., Voelter V., Romero P., Speiser D.E., Leyvraz S. Immuno-monitoring of CD8+ T cells in whole blood versus PBMC samples. J Immunol Methods 2006, 309(1-2):192-199.
16. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15(6):825-828.
17. Cox D. Regression models and life tables (with discussion). J R Stat Soc 1972, 34:187-220.
18. Yakoub-Agha I., Mesnil F., Kuentz M., Boiron J.M., Ifrah N., Milpied N., et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006, 24(36):5695-5702.
19. Coghill J.M., Carlson M.J., Panoskaltsis-Mortari A., West M.L., Burgents J.E., Blazar B.R., et al. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7on donor T cells. Blood 2010, 115(23):4914-4922.
20. Chakraverty R., Cote D., Buchli J., Cotter P., Hsu R., Zhao G., et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J Exp Med 2006, 203(8):2021-2031.
21. Fujiwara H., Sconocchia G., Melenhorst J., Eniafe R., Nakamura R., Hensel N., et al. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator-responder pairs. Bone Marrow Transplant 2003, 32(4):371-378.
22. Michalek J., Collins R.H., Durrani H.P., Vaclavkova P., Ruff L.E., Douek D.C., et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences. Proc Natl Acad Sci U S A 2003, 100(3):1180-1184.
23. Yang Y.G., Qi J., Wang M.G., Sykes M. Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8T cells. Blood 2002, 99(11):4207-4215.
24. Tiberghien P. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J Intern Med 2001, 249(4):369-377.
25. Andre-Schmutz I., Le Deist F., Hacein-Bey S., Hamel Y., Vitetta E., Schindler J., et al. Donor T lymphocyte infusion following ex vivo depletion of donor anti-host reactivity by a specific anti-interleukin-2receptor P55chain immunotoxin. Transplant Proc 2002, 34(7):2927-2928.
26. Anderson B.E., McNiff J., Yan J., Doyle H., Mamula M., Shlomchik M.J., et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest 2003, 112(1):101-108.
27. Adams A.B., Williams M.A., Jones T.R., Shirasugi N., Durham M.M., Kaech S.M., et al. Heterologous immunity provides a potent barrier to transplantation tolerance. J Clin Invest 2003, 111(12):1887-1895.
28. Bondanza A., Valtolina V., Magnani Z., Ponzoni M., Fleischhauer K., Bonyhadi M., et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood 2006, 107(5):1828-1836.
29. Chen B.J., Deoliveira D., Cui X., Le N.T., Son J., Whitesides J.F., et al. Inability of memory T cells to induce graft-versus-host disease is a result of an abortive alloresponse. Blood 2006, 109(7):3115-3123.
30. Foster A.E., Marangolo M., Sartor M.M., Alexander S.I., Hu M., Bradstock K.F., et al. Human CD62L-memory T cells are less responsive to alloantigen stimulation than CD62L+ naive T cells: potential for adoptive immunotherapy and allodepletion. Blood 2004, 104(8):2403-2409.
31. Xystrakis E., Bernard I., Dejean A.S., Alsaati T., Druet P., Saoudi A. Alloreactive CD4T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset. Eur J Immunol 2004, 34(2):408-417.
32. Beilhack A., Schulz S., Baker J., Beilhack G.F., Wieland C.B., Herman E.I., et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood 2005, 106(3):1113-1122.
33. Dutt S., Ermann J., Tseng D., Liu Y.P., George T.I., Fathman, et al. L-selectin and beta7integrin on donor CD4T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood 2005, 106(12):4009-4015.
34. Kim Y.M., Sachs T., Asavaroengchai W., Bronson R., Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest 2003, 111(5):659-669.
35. Li B., New J.Y., Tay Y.K., Goh E., Yap E.H., Chan S.H., et al. Delaying acute graft-versus-host disease in mouse bone marrow transplantation by treating donor cells with antibodies directed at L-selectin and alpha4-integrin prior to infusion. Scand J Immunol 2004, 59(5):464-468.
36. Sasaki M., Hasegawa H., Kohno M., Inoue A., Ito M.R., Fujita S. Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice. J Immunol 2003, 170(1):588-596.
37. Wysocki C.A., Panoskaltsis-Mortari A., Blazar B.R., Serody J.S. Leukocyte migration and graft-versus-host disease. Blood 2005, 105(11):4191-4199.
38. Arstila T.P., Casrouge A., Baron V., Even J., Kanellopoulos J., Kourilsky P. A direct estimate of the human alphabeta T cell receptor diversity. Science 1999, 286(5441):958-961.
39. Macallan D.C., Wallace D., Zhang Y., De Lara C., Worth A.T., Ghattas H., et al. Rapid turnover of effector-memory CD4+ T cells in healthy humans. J Exp Med 2004, 200(2):255-260.
40. Rufer N., Zippelius A., Batard P., Pittet M.J., Kurth I., Corthesy P., et al. Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions. Blood 2003, 102(5):1779-1787.
41. Geginat J., Sallusto F., Lanzavecchia A. Cytokine-driven proliferation and differentiation of human naive central memory and effector memory CD4+ T cells. Pathol Biol 2003, 51(2):64-66.
42. Maus M.V., Kovacs B., Kwok W.W., Nepom G.T., Schlienger K., Riley J.L., et al. Extensive replicative capacity of human central memory T cells. J Immunol 2004, 172(11):6675-6683.
43. Ermann J., Hoffmann P., Edinger M., Dutt S., Blankenberg F.G., Higgins J.P., et al. Only the CD62L+ subpopulation of CD4+CD25+ regulatory T cells protects from lethal acute GVHD. Blood 2005, 105(5):2220-2226.
44. Huehn J., Siegmund K., Lehmann J.C., Siewert C., Haubold U., Feuerer M., et al. Developmental stage phenotype and migration distinguish naive- and effector/memory-like CD4+ regulatory T cells. J Exp Med 2004, 199(3):303-313.
45. Taylor P.A., Panoskaltsis-Mortari A., Swedin J.M., Lucas P.J., Gress R.E., Levine B.L., et al. L-Selectin(hi) but not the L-selectin(lo) CD4+25+ T-regulatory cells are potent inhibitors of GVHD and BM graft rejection. Blood 2004, 104(12):3804-3812.